ORIGINAL ARTICLE

# Positive pre-resection pleural lavage cytology is associated with increased risk of lung cancer recurrence in patients undergoing surgical resection: a meta-analysis of 4450 patients

Srdjan Saso, <sup>1</sup> Christopher Rao, <sup>2</sup> Hutan Ashrafian, <sup>2</sup> Sadaf Ghaem-Maghami, <sup>1</sup> Ara Darzi, <sup>2</sup> Thanos Athanasiou <sup>2</sup>

► Additional appendices are published online only. To view these files please visit the journal online (http://thorax.bmj.com/content/67/6.toc).

<sup>1</sup>Division of Surgery and Cancer, Institute of Reproductive & Developmental Biology, Imperial College London, Hammersmith Hospital Campus, London, UK <sup>2</sup>Department of Biosurgery, Surgical Technology and Surgical Epidemiology Unit, Imperial College London, St Mary's Hospital, London, UK

#### Correspondence to

Srdjan Saso, Clinical Research Fellow, Division of Surgery and Cancer, Institute of Reproductive & Developmental Biology, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 ONN, UK; srdjan.saso@imperial.ac.uk

Received 5 May 2011 Accepted 20 December 2011 Published Online First 27 January 2012

## **ABSTRACT**

**Introduction** The value of pleural lavage cytology (PLC) in assessing the prognosis of early stage lung cancer is still controversial. No systematic review has investigated the relationship between PLC and lung cancer recurrence. Our primary goal was to investigate the association between positive pre-resection PLC and pleural, distant and overall tumour recurrence in patients undergoing surgical resection.

Methods Medline, EMBASE and Google Scholar databases were searched up to 2011. All studies reporting relevant outcomes in both patient groups were included. Data were extracted for the following outcomes of interest: overall, local and distant recurrence; and freedom from death (survival—overall and patients with stage I disease only). Random effects meta-analysis was used to aggregate the data. Sensitivity and heterogeneity analysis were performed. **Results** A meta-analysis of eight studies at maximum follow-up demonstrated a significant association between positive pre-resection PLC and increased risk of post-resection overall recurrence (OR 4.82, 95% CI 2.45 to 9.51), pleural recurrence (OR 9.89, 95% CI 5.95 to 16.44) and distant cancer recurrence (OR 3.18, 95% CI 1.57 to 6.46). Furthermore, a meta-analysis of 17 studies suggested that positive pre-resection PLC was also associated with unfavourable survival (HR 2.08, 95% CI 1.71 to 2.52). These findings were supported by sensitivity analysis.

**Discussion** Positive pre-resection PLC is associated with higher overall, distant and local tumour recurrence and unfavourable patient survival outcomes. This technique may therefore act as a predictor of tumour recurrence and adverse survival. Furthermore, its role in including adjuvant chemotherapy to the management protocol should be investigated within randomised controlled trials.

#### INTRODUCTION

Lung cancer is the leading cause of cancer-related mortality throughout the world, accounting for 28% of all US cancer-related deaths. The 5-year overall survival rate remains dramatically low, varying from 8% in Europe to 15.7% in the USA. The most likely explanation lies in the tendency of lung cancer to spread at a microscopic level in its early stage.

# Key messages

# What is the key question?

Can positive pre-resection pleural lavage cytology (PLC) act as a predictor for overall, pleural and distant lung cancer recurrence?

## What is the bottom line?

 Positive pre-resection PLC is associated with higher overall, distant and local tumour recurrence.

# Why read on?

► To assess whether positive PLC can 'map out' recurrence risk at an earlier time point and with greater precision than current staging methods, thus altering management strategies.

A need has arisen for methods with the potential to detect microscopic spread. Such methods would allow one to 'map out' recurrence risk at an earlier time point and with greater precision than current staging techniques. <sup>4</sup> Current staging is based on macroscopic assessment of local, lymphatic and haematogenous spread of cancer. Based on the stage, a decision is made as to whether surgical resection is appropriate or not. <sup>5</sup> The current TNM staging system does not accurately predict prognosis of recurrence for patients with early stage disease, with a significant number of recurrences and poor survival outcomes occurring in this group. <sup>3</sup>

Pleural lavage cytology (PLC) is a technique which may increase the accuracy of current prediction models for cancer recurrence in early stage disease. Since its first use in 1958, several studies have clearly demonstrated a link between the presence of malignant cells in PLC and subsequent early stage pleural dissemination and poor prognosis. However, PLC has not currently been shown to be an independent predictor for recurrence or survival, nor is it included in the present TNM classification.

Two meta-analytical studies have addressed the issue of whether PLC can act as an independent predictor for survival in patients with lung cancer.  $^{6\,13}$  Both concluded that positive PLC is a strong

prognostic factor for survival. However, these meta-analyses did not assess the relationship between positive PLC and recurrence. Additionally, their pre-resection data were derived from only nine trials and 11 centres, respectively, excluding important studies. Finally, the study by Lim *et al* did not differentiate between pre-resection and post-resection PLC. <sup>13</sup>

The main aim of this study was to test the following three hypotheses:

- 1. Positive pre-resection PLC is associated with overall lung cancer recurrence.
- 2. Positive pre-resection PLC is associated with specifically pleural and distant lung cancer recurrence.
- 3. Positive pre-resection PLC is associated with poor survival outcomes in all patients with lung cancer and in those with stage I disease only.

## **METHODS**

## Literature search

A literature search was performed using Pubmed, comprising more than 21 million citations for biomedical literature from Medline, life science journals, online books, and Cochrane Library and Google Scholar engines for all relevant studies up until January 2011. The following headings were used in all three databases: Lung cancer, Pulmonary cancer, Lung resection; Pulmonary resection. A Pubmed search was also performed under the following MeSH headings: Lung neoplasm; Non-small cell lung cancer. The results for each heading were subsequently combined with the results from a separate search under the heading: 'Pleural lavage'. The search was expanded using the 'related articles' function and by considering reference lists of all studies, including review articles.

# **Outcomes of interest**

Positive and negative pre-resection PLC were compared. The primary outcome of interest was whether positive pre-resection PLC was a valid predictor of postoperative pleural and distant cancer recurrence. The secondary outcome of interest was whether positive pre-resection PLC was a valid predictor of worse overall survival in patients with all stages of disease (I—IV), and in patients with stage I disease in particular.

# Inclusion and exclusion criteria

Studies which compared patient outcomes related to positive and negative pre-resection PLC were considered for inclusion. To be included in the actual meta-analysis, the study had to either report recurrence data or results allowing calculation of survival data. If several articles reported on the same patient cohort, the most recent article or the article with the greatest deal of information was selected. No language restrictions were applied.

Studies reporting post-resection PLC were not of interest. Review articles and studies in which it was not possible to extract the primary outcome of interest were excluded.

## **Data extraction**

Two reviewers (SS and CR) independently performed literature searches and extracted data according to a predefined search protocol. In the case of discrepancy, a consensus decision was achieved by discussion, and if necessary, adjudication by a third reviewer (TA). Patient and cancer characteristics (online appendix A), local and distant cancer recurrence rates (table 1), and survival outcomes were extracted. Pre-resection PLC was defined in all studies as PLC performed immediately after thoracotomy and prior to any pleural parenchymal manipulation. As the authors of those studies described only a single pre-resection PLC in the relevant study methods section, we believe that one pre-resection PLC was performed before it was considered to be negative.

# Statistical analysis

A meta-analysis was conducted according to PRISMA, MOOSE and Cochrane Collaboration guidelines.  $^{14-16}$  OR was used as the summary statistic for recurrence rates. An OR >1 implied a higher probability of recurrence for the positive PLC group. HR was used as the summary statistic for survival data. Several methods have been described to extract survival data from observational studies, each of these with different limitations.  $^{17}$  A HR >1 implied a worse survival outcome for the positive PLC group. OR and HR were considered statistically significant at the p <0.05 level if the 95% CI did not include the value one.

Aggregation of the overall rates of the primary and secondary outcomes were performed with the Mantel—Haenszel method.  $^{18}$  We used a random-effects model which assumes that there is variation among studies because this model better accounts for heterogeneity between studies.  $^{19}$   $^{20}$ 

Analysis was conducted using the statistical software Review Manager V.5.2 (The Cochrane Collaboration, Oxford). For the meta-regression analysis, we used weighted least squares regression with SPSS V.19 for Windows.

# Assessment of data validity and heterogeneity (recurrence)

Three different strategies using quantitative and graphical comparisons were used to assess recurrence data validity and heterogeneity:

- 1. Sensitivity analysis through examination of the following subgroups:
- a. study size (patient number >350)
- b. positive PLC percentage (<5%, 5-10%, 10-20%, >20%)
- c. study quality
- d. survival data only: annual follow-up (1-5 years).

 Table 1
 Cancer recurrence data

	Taniguchi (2009) <sup>9</sup>		Shintani (2009) <sup>10</sup>		Kawachi (2009) <sup>11</sup>		Higashiyama (2009) <sup>12</sup>		Satoh (2007) <sup>3</sup>		Higashiyama (1997) <sup>24</sup>		Buhr (1997) <sup>25</sup>		Okumura (1991) <sup>34</sup>	
	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg
Total	14	282	67	1182	41	527	89	590	41	812	38	268	132	210	22	135
Recurrence number	9	64	32	384	24	141	56	NS	32	177	21	99	96	35	15	47
Pleural recurrence	NS	NS	3	7	7	31	21	14	8	10	7	5	22	4	2	0
Distant metastases	4	27	24	324	13	69	32	NS	23	134	11	70	78	23	9	34
Loco-regional recurrence	2	21	5	53	10	50	NS	NS	2	39	NS	NS	NS	NS	4	13
Local alone	NS	NS	NS	NS	NS	NS	24	NS	NS	NS	4	17	18	12	4	13
Local and distant	3	16	NS	NS	2	10	NS	NS	NS	NS	6	11	NS	NS	NS	NS

Neg, negative; NS, not specified; Pos, positive.

# Lung cancer

- 2. Heterogeneity assessment through the  $I^2$  statistic: heterogeneity of treatment effects among studies was assessed using the  $I^2$  statistic. This represents the proportion of total variation observed among the trials attributable to differences among trials rather than sampling error or chance.<sup>21</sup>
- 3. Assessment of the following confounders in a metaregression analysis of recurrence data to identify if the results are affected:
- a. study size (patient number >350)
- b. cut-off of positive PLC (percentage <5%, 5–10%, 10–20%, >20%)
- c. study quality
- d. publication year (pre-2005 and post-2005)
- 4. Graphical exploration to evaluate publication bias in studies reporting recurrence data by assessing for asymmetry and evidence of outliers.  $^{\rm 22~23}$

# **Quality scoring**

There was considerable variation among studies in the proportion of patients with a positive PLC. To explore the possible


**Figure 1** Summary of the results of the literature search.

causes of this variation, we created a 'checklist' (online appendix B) which acted as a tool for the assessment of methodological quality and heterogeneity in study design. We attributed one point or a zero to each question answered 'yes' or 'no/not specified', respectively (online appendix C). The median quality score was 11, and studies scoring more than this were deemed to be of high quality and included in the subgroup analysis.

# **RESULTS**

## Selected studies

The literature search identified 818 studies published between 1991 and 2010. On the basis of title and abstract, 154 articles were obtained and reviewed in full. Eight studies including 4450 patients reported data relevant to the primary outcome of interest: recurrence. Data relevant to the secondary outcome of interest—survival—were reported in the same eight studies and nine new studies. In total, 17 articles met the inclusion and exclusion criteria (figure 1).  $^{8}$ 



Four were prospective observational  $^3$   $^{25}$   $^{30}$   $^{31}$  and 13 were retrospective  $^{8-12}$   $^{24}$   $^{26}$   $^{28}$   $^{29}$ ; all were non-randomised. They contained a total of 9935 patients, of whom 709 (7.14%) had positive pre-resection PLC.

# Meta-analysis of recurrence data

## Overall recurrence

Positive pre-resection PLC was associated with a higher likelihood of overall, pleural and distant recurrence in comparison to negative pre-resection PLC. Seven studies reported overall recurrence data (figure 2) $^{3}$   $^{9-11}$   $^{24}$   $^{25}$   $^{34}$  for 3771 patients of whom 355 (9.41%) had positive pre-resection PLC. A meta-analysis

demonstrated a statistically significant OR of 4.82 (95% CI 2.45 to 9.51;  $\gamma^2$  of heterogeneity 40.44 (p<0.00001)).

### Pleural recurrence only

Seven studies reported pleural recurrence (4154 patients of whom 430 (10.4%) had positive pre-resection PLC). OR was statistically significant at 9.89 (95% CI 5.95 to 16.44;  $\chi^2$  of heterogeneity 8.91 (p=0.180)).  $^3$   $^{10-12}$   $^{24}$   $^{25}$   $^{34}$ 

# Distant recurrence only

Seven studies reported distant recurrence (3771 patients of whom 355 (9.41%) had positive pre-resection PLC). OR was

Figure 2 Forest plot comparing recurrence rates: 'positive PLC versus negative PLC' groups. PLC, pleural lavage cytology.

1.2.1 Overall recurrence   Suhr 1997   96   132   35   210   4.3%   13.33 (7.87 to 22.60)   Higashiyama 1997   21   38   99   268   4.0%   2.11 (1.06 to 4.19)   Kawachi 2009   24   41   141   527   4.1%   3.86 (2.02 to 7.41)   Okumura 1991   15   22   47   135   3.4%   4.01 (1.53 to 10.53)   Satoh 2007   32   41   177   812   3.8%   12.76 (5.98 to 27.22)   Shintani 2009   32   67   384   1182   4.3%   1.90 (1.16 to 3.12)   Taniguchi 2009   9   14   64   282   3.1%   6.13 (1.98 to 18.95)   Subtotal (95% CI)   355   3416   27.0%   4.82 (2.45 to 9.51)   Total events   229   947   Heterogeneity: τ²=0.69; χ²=40.44, df=6 (p<0.00001); l²=85%   Test for overall effect: Z=4.54 (p<0.00001)   1.2.2 Local recurrence   Buhr 1997   18   132   12   210   3.8%   2.61 (1.21 to 5.60)   Higashiyama 1997   4   38   17   268   3.1%   1.74 (0.55 to 5.47)   Okumura 1991   18   132   12   210   3.8%   2.61 (1.21 to 5.60)   Subtotal (95% CI)   302   688   10.7%   2.42 (1.48 to 3.95)   Total events   40   41   Heterogeneity: τ²=0.00; χ²=0.39 (df=2 (p=0.82); l²=0%   Test for overall effect: Z=3.54 (p=0.0004)   1.2.3 Locoregional recurrence   Kawachi 2009   10   41   50   527   3.8%   3.08 (1.42 to 6.65)   Cokumura 1991   4   22   13   135   2.9%   2.09 (0.61 to 7.10)   Satoh 2007   2   41   39   812   2.5%   1.02 (0.24 to 4.36)   Shihtani 2009   5   67   53   1182   3.4%   1.72 (0.66 to 4.45)   Taniguchi 2009   2   14   21   282   2.3%   2.07 (0.43 to 9.87)   Subtotal (95% CI)   185   2938   15.0%   2.13 (1.32 to 3.45)								
12.1 Overall recurrence								
Bury 1907	Study		Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Higashly ama 1997								
Kawechi 2009								
Okumura 1991 15 22 47 135 3.4% 4.01 (1.53 to 10.53)  Saloha 2007 32 41 177 812 3.8% 4.01 (1.53 to 10.53)  Shintani 2009 32 67 384 1182 4.3% 1.90 (1.16 to 3.12)  Transpuchi 2009 9 14 64 292 3.1% 6.13 (1.99 to 18.95)  Subtotal (95% Cl) 23 355 3416 27.0% 4.82 (2.45 to 9.51)  Total events 940 4.4 dr=6 (p<0.00001); P=85%  Test for overall effect. Z=4.54 (p<0.00001)  1.2.2 Local recurrence  Burn 1997 18 132 12 210 3.8% 2.61 (1.21 to 5.60)  Chamura 1991 18 132 12 210 3.8% 2.61 (1.10 to 5.60)  Subtotal (95% Cl) 302 688 10.7% 2.42 (1.48 to 3.95)  Total events 1991 18 132 12 210 3.8% 2.61 (1.21 to 5.60)  Subtotal (95% Cl) 302 688 10.7% 2.42 (1.48 to 3.95)  Total events 1991 18 132 12 210 3.8% 3.08 (1.42 to 6.65)  Chamura 1991 18 132 12 210 3.8% 3.08 (1.42 to 6.65)  Chamura 1991 18 132 12 210 3.8% 3.08 (1.42 to 6.65)  Chamura 1991 18 132 12 210 3.8% 3.08 (1.42 to 6.65)  Chamura 1991 18 132 12 210 3.8% 3.08 (1.42 to 6.65)  Chamura 1991 4 22 13 135 2.9% 1.02 (0.24 to 4.36)  Shibtotal (95% Cl) 302 688 10.7% 2.49 (1.61 to 7.10)  Satoh 2007 2 41 39 812 2.5% 1.02 (0.24 to 4.36)  Shibtotal (95% Cl) 1627 14 12 282 2.3% 1.72 (0.66 to 4.45)  Total events 23 12 4 210 3.2% 1.72 (0.66 to 4.45)  Total events 24 10 10 (p=0.002)  1.2.4 Pleural recurrence  Burn 1997 22 132 4 210 3.2% 1.03 (3.46 to 30.64)  Higsathyama 2009 2 1 69 14 590 3.9% 12.71 (6.18 to 26.14)  Frest for overall effect. Z=3.10 (p=0.002)  1.2.4 Pleural recurrence  Burn 1997 78 13 2 28 20 0 135 0.9% 33.05 (1.53 to 713.13)  Shibtotal (95% Cl) 430 3724 20.5% 9.89 (5.95 to 16.44)  Philasthyama 2009 13 41 69 527 3.9% 3.09 (1.55 to 8.03)  Okumura 1991 2 22 0 135 0.9% 33.05 (1.53 to 713.13)  Shibtotal (95% Cl) 430 3724 20.5% 9.89 (5.95 to 16.44)  Philasthyama 2009 13 41 69 527 3.9% 3.09 (1.55 to 6.24)  Okumura 1991 2 22 0 0.55 3.9% 3.09 (1.52 to 6.24)  Okumura 1991 3 23 41 134 812 4.9% 6.47 (3.40 to 12.31)  Shibtotal (95% Cl) 450 3.55 3.46 (6.60 0.0001); P=86%  Test for overall effect. Z=8.20 (p=0.0001); P=86%  Test for overall effect. Z=8.20 (p=0.0001); P=86%  Test for overal	Higashiyama 1997							
Saloh 2007 32 41 177 812 3.8% 12.76 (5.98 to 27.22) Shiritani 2009 32 67 384 1192 4.3% 1.90 (1.16 to 3.12) Tanigueri 2009 9 14 64 292 3.1% 6.13 (1.98 to 18.95) Stathotal (95% C) 355 3416 27.0% 4.82 (2.45 to 9.51) Total events 228 947 3416 27.0% 4.82 (2.45 to 9.51) Total events 40 41 Higsathyama 1997 4 38 132 12 210 3.8% 2.61 (1.21 to 5.60) Stathotal (95% C) 302 688 10.7% 2.42 (1.48 to 3.95) Total events 40 41 Helercogeneity: r²=0.00; x²=0.30, dr=2 (p=0.82); r²=0% Test for overall effect: Z=3.54 (p=0.0004)  1.2.3 Locor egional recurrence Kawachi 2009 10 41 50 527 3.8% 3.08 (1.42 to 6.65) Okumura 1991 4 22 13 135 2.9% 2.09 (0.61 to 7.10) Saloh 2007 2 41 39 812 2.5% 1.02 (0.24 to 4.36) Shirlani 2009 5 67 55 1182 3.4% 1.72 (0.66 to 4.45) Tanigueri 2009 2 14 21 282 2.3% 2.07 (0.43 to 9.87) Shirlani 2009 5 67 55 1182 3.4% 1.72 (0.66 to 4.45) Total events 40 Helercogeneity: r²=0.00; x²=0.90, d.f=4 (p=0.72); r²=0% Test for overall effect: Z=3.10 (p=0.002)  12.2 Pleural recurrence Buhr 1997 7 38 5 288 2.9% 11.88 (3.55 to 39.69) Higsathyama 2009 2 18 14 590 3.9% 12.71 (6.18 to 26.14) Kawachi 2009 7 41 31 527 3.6% 3.9% 3.90 (1.53 to 713.13) Saloh 2007 8 41 10 812 3.4% 12.70 (0.61 to 5.47) Shirlani 2009 5 67 57 1182 2.4% 12.70 (0.50 to 4.45) Total events 40 41 41 41 41 41 41 41 41 41 41 41 41 41	Kawachi 2009	-					3.86 (2.02 to 7.41)	
Shintani 2009 32 67 384 1182 4.3% 1.90 (1.16 to 3.12) Taniguchi 2009 9 14 64 282 3.1% 6.13 (1.98 to 18.95) Stuttotal (95% C) 355 3416 27.0% 4.82 (2.45 to 9.51) Total events 229 947 Heterogeneity: r²=0.69; r²=40.44, df=6 (p<0.0001); P²=85% Test for overal effect. Z=4.54 (p<0.00001)  1.2.2 Local recurrence Buhr 1937 18 132 12 210 3.8% 2.61 (1.21 to 5.60) Chumrura 1991 18 132 12 210 3.8% 2.61 (1.21 to 5.60) Stuttotal (95% C) 302 688 10.7% 2.42 (1.48 to 3.95) Total events (1.29 0.0); r²=0.03; df=2 (p=0.82); P=0% Test for overal effect. Z=3.54 (p=0.004)  1.2.3 Locoregional recurrence Kawachi 2009 10 41 50 527 3.8% 3.08 (1.42 to 6.65) Chumrura 1991 4 22 13 39 812 2.5% 10.2 (0.24 to 4.36) Shinbani 2009 2 14 21 282 2.3% 2.07 (0.43 to 8.97) Suithotal (95% C) 185 2988 15.0% 2.13 (1.32 to 3.45) Total events 22 Heterogeneity: r²=0.00; r²=2.08, df=4 (p=0.72); P=0% Test for overal effect. Z=3.50 (p=0.0002)  1.2.4 Pleural recurrence Buhr 1997 22 132 4 210 3.2% 12.70 (0.43 to 8.97) Suithotal (95% C) 185 27 38 39 3.08 (1.52 to 6.45) Taniguchi 2009 2 14 21 282 2.3% 2.07 (0.43 to 8.97) Suithotal (95% C) 185 298 15.0% 2.13 (1.32 to 3.45) Total events 23 Heterogeneity: r²=0.00; r²=2.08, df=4 (p=0.72); P=0% Test for overal effect. Z=3.50 (p=0.002)  1.2.4 Pleural recurrence Buhr 1997 22 132 4 210 3.2% 12.7 (6.18 to 26.14) Kawachi 2009 7 41 31 527 3.6% 3.39 (1.53 to 73.13) Saltoh 2007 8 41 10 812 3.4% 19.44 (72 to 10.52 47) Shintani 2009 3 67 7 1192 2.6% 7.87 (1.99 to 31.14) Shintani 2009 3 67 7 1192 2.6% 7.87 (1.99 to 31.14) Shintani 2009 7 8 13 13 72 3.6% 3.9% 3.08 (1.52 to 6.24) Okumrura 1991 9 2 23 13 4 59 3.9% 3.08 (1.52 to 6.24) Okumrura 1991 9 2 34 31 35 5.9% 3.9% 3.08 (1.52 to 6.24)  Okumrura 1991 9 2 34 31 35 5.9% 3.9% 3.08 (1.52 to 6.24) Okumrura 1991 9 2 34 31 35 5.9% 3.9% 3.08 (1.52 to 6.24)  Okumrura 1991 9 2 34 31 34 69 527 3.9% 3.08 (1.52 to 6.24)  Okumrura 1991 9 2 34 31 35 5.9% 3.08 (1.52 to 6.24)  Okumrura 1991 9 2 34 31 35 5.9% 3.08 (1.52 to 6.24)  Okumrura 1991 9 2 34 31 35 5.9% 3.08 (1.52 to 6.24)  Okumrura 1991 9								<del></del>
Tanipuchi 2009 9 14 84 282 3.1% 6.13 (1.98 to 18.96) Subtotal (99% c)) 355 3.16 27.0% 4.82 (2.45 to 9.51) Total events 229 947 Helevenens 229 947 Helevenens (1.26 (p<0.00001); P=85% Test for overall effect: Z=4.54 (p<0.00001); P=85% Total events 40 41 Heletrogeneity: r=0.00: y=0.39, d=2 (p=0.82); P=0% Test for overall effect: Z=3.54 (p=0.0004)  12.3 Locategional recurrence Kawachi 2009 10 41 50 527 3.8% 3.08 (1.42 to 6.65) Okumura 1991 4 22 13 135 2.9% 2.09 (0.61 to 7.10) Salon 2007 2 41 39 812 2.5% 1.02 (0.24 to 4.36) Shintani 2009 5 67 55 1182 3.4% 1.72 (0.66 to 4.45) Tanipuchi 2009 2 14 2 182 22.3% 2.07 (0.43 to 9.87) Subtota (95% c)) 185 2.938 15.0% Total events 42 16 42 (p=0.72); P=0% Test for overall effect: Z=3.10 (p=0.002)  12.2 Pleural recurrence  Buhr 1997 7 38 5 288 2.9% 11.88 (3.55 to 39.69) Higashiyama 2009 2 18 9 14 590 3.9% 3.05 (1.53 to 713.13) Salon 2007 8 41 10 812 3.4% 127 (1.618 to 26.14) Kawachi 2009 7 41 31 527 3.6% 3.9% 3.29 (1.53 to 19.31) Shintani 2009 5 67 7 1182 2.6% 7.87 (1.99 to 31.14) Shintani 2009 7 8 13 2 22 210 4.2% 11.74 (6.18 to 26.14) Salon 2007 8 41 10 812 3.4% 12.4% 12.4% 12.5% 12.5% 13.30 (1.33 to 15.31 to 15.3					812		12.76 (5.98 to 27.22)	
Subtotal (95% CI) 355 3416 27.0% 4.82 (2.45 to 9.51) Total events 229 947 Feat for overall effect. 2=4.54 (p<0.00001): P=85% Feat for overall effect. 2=5.54 (p<0.00001): P=85% Feat for overall effect. 2=3.54 (p<0.0001): P=0.00001 Feat for overall effect. 2=3.54 (p<0.0001): P=0.00001 Feat for overall effect. 2=3.54 (p<0.00001): P=0.00001 Feat for overall effect. 2=3.50 (p<0.00001): P=0.000001 Feat for overall effect. 2=3.50 (p<0.00001): P=0.00001 Feat for overall effect. 2=3.50 (p<0.00001): P=0.000001 Feat for overall effect. 2=3.50 (p<0.00001): P=0.000001 Feat for overall effect			-				,	
Total events	Taniguchi 2009 Subtotal (95% CI)	9		64				
Heterogeneity: r²=0.68; y²=40.44, dr=6 (p<0.00001); P²=85% Test for overall effect: Z=4.54 (p<0.00001); P²=85% Test for overall effect: Z=3.54 (p<0.00001); P²=85% Test for overall effect: Z=3.54 (p<0.00001); P²=85% Test for overall effect: Z=3.54 (p<0.0001); P²=85% Test for overall effect: Z=3.10 (p<0.0001); P²=85% Test for overall effect: Z=8.30 (p<0.0001); P²=85% Test for overall effect: Z=8.30 (p<0.0001); P²=85% Test for overall effect: Z=8.30 (p<0.0001); P²=86% Test for overall effect: Z=8.30 (p<0.0001)		229		947			,	
Test for overall effect: Z=4.54 (p<0.00001)  1.2.2 Local recurrence  Buhr 1997 18 132 12 210 3.8% 2.61 (1.21 to 5.60)    Higgshiyama 1997 4 38 17 268 3.1% 1.74 (0.55 to 5.47)			df=6 (		1)· I <sup>2</sup> =85	9/6		
Buhr 1997 18 132 12 210 3.8% 2.61 (1.21 to 5.60)  Higashiyama 1997 4 38 17 288 3.1% 1.74 (0.55 to 5.47)  Columnura 1991 18 132 12 210 3.8% 2.61 (1.21 to 5.60)  Subtotal (195% CI) 302 688 10.7% 2.42 (1.48 to 3.95)  Total events  Heterogeneity: r²=0.00; r²=0.39, dr=2 (p=0.82); r²=0%  Test for overall effect: Z=3.54 (p=0.0004)  1.2.3 Locoregional recurrence  Kawachi 2009 10 41 50 527 3.8% 3.08 (1.42 to 6.65)  Okumrura 1991 4 22 13 135 2.9% 2.09 (0.61 to 7.10)  Satisho 2007 2 41 39 812 2.5% 1.02 (0.24 to 4.36)  Shintani 2009 5 67 53 1182 3.4% 1.72 (0.66 to 4.45)  Taniguchi 2009 2 14 2 22 23% 2.07 (0.43 to 9.87)  Subtotal (95% CI) 185 2.938 15.0% 2.13 (1.32 to 3.45)  Total events  Heterogeneity: r²=0.00; r²=2.08, dr=4 (p=0.72); r²=0%  Test for overall effect: Z=3.10 (p=0.002)  1.2.4 Pleural recurrence  Buhr 1997 7 38 5 288 2.9% 11.88 (3.55 to 39.69)  Higashiyama 2009 2 18 81 4 550 3.9% 12.71 (6.18 to 26.14)  Kawachi 2009 7 41 31 527 3.6% 3.30 (3.46 to 30.64)  Higashiyama 2009 3 67 7 1182 2.6% 7.87 (1.99 to 31.14)  Subtotal (95% CI) 430 3724 20.5% 9.89 (5.95 to 16.44)  Total events					.,,. 00	,,,		
Buhr 1997 18 132 12 210 3.8% 2.61 (1.21 to 5.60)  Higashiyama 1997 4 38 17 288 3.1% 1.74 (0.55 to 5.47)  Columnura 1991 18 132 12 210 3.8% 2.61 (1.21 to 5.60)  Subtotal (195% CI) 302 688 10.7% 2.42 (1.48 to 3.95)  Total events  Heterogeneity: r²=0.00; r²=0.39, dr=2 (p=0.82); r²=0%  Test for overall effect: Z=3.54 (p=0.0004)  1.2.3 Locoregional recurrence  Kawachi 2009 10 41 50 527 3.8% 3.08 (1.42 to 6.65)  Okumrura 1991 4 22 13 135 2.9% 2.09 (0.61 to 7.10)  Satisho 2007 2 41 39 812 2.5% 1.02 (0.24 to 4.36)  Shintani 2009 5 67 53 1182 3.4% 1.72 (0.66 to 4.45)  Taniguchi 2009 2 14 2 22 23% 2.07 (0.43 to 9.87)  Subtotal (95% CI) 185 2.938 15.0% 2.13 (1.32 to 3.45)  Total events  Heterogeneity: r²=0.00; r²=2.08, dr=4 (p=0.72); r²=0%  Test for overall effect: Z=3.10 (p=0.002)  1.2.4 Pleural recurrence  Buhr 1997 7 38 5 288 2.9% 11.88 (3.55 to 39.69)  Higashiyama 2009 2 18 81 4 550 3.9% 12.71 (6.18 to 26.14)  Kawachi 2009 7 41 31 527 3.6% 3.30 (3.46 to 30.64)  Higashiyama 2009 3 67 7 1182 2.6% 7.87 (1.99 to 31.14)  Subtotal (95% CI) 430 3724 20.5% 9.89 (5.95 to 16.44)  Total events	1.2.2 Local recurrence	,						
Higashiyama 1997 4 38 17 268 3.1% 1.74 (0.55 to 5.47) Okumura 1991 18 132 12 210 3.8% 2.61 (1.21 to 5.60) Subtotal (99% CI) 302 688 10.7% 2.42 (1.48 to 3.95) Total events Heterogeneity: *2*=0.00; *2*=0.39, df=2 (p=0.82); i²=0% Test for overall effect: Z=3.54 (p=0.0004)  1.2.3 Locoregional recurrence Kawachi 2009 10 41 50 527 3.8% 3.08 (1.42 to 6.65) Okumura 1991 4 22 13 135 2.9% 2.09 (0.61 to 7.10) Saloh 2007 2 41 39 812 2.5% 1.02 (0.24 to 4.36) Shithani 2009 5 67 53 1182 3.4% 1.72 (0.66 to 4.45) Taniguchi 2009 2 14 21 262 2.3% 2.07 (0.43 to 9.87) Subtotal (199% CI) 185 2938 15.0% 2.13 (1.32 to 3.45) Total events Heterogeneity: *2*=0.00; *2*=2.08, df=4 (p=0.72); i²=0% Test for overall effect: Z=3.10 (p=0.002)  1.2.4 Pleural recurrence  Buhr 1997 2 2 132 4 210 3.2% 10.30 (3.46 to 30.64) Higashiyama 2009 2 7 41 31 527 3.8% 3.29 (1.35 to 8.03) Okumura 1991 2 22 0 135 0.9% 33.05 (1.53 to 713.13) Saloh 2007 8 41 10 812 3.4% 19.44 (7.20 to 52.47) Shintani 2009 3 67 7 1182 2.6% 7.87 (1.99 to 31.14) Subtotal (199% CI) 430 3724 20.5% 9.89 (6.95 to 16.44) Total events 70 140 140 140 140 140 140 140 140 140 14			132	12	210	3 8%	2 61 (1 21 to 5 60)	l——
Okumura 1981 18 132 12 210 3.8% 2.61 (1.21 to 5.60) Subtota (19% CI) 302 688 10.7% 2.42 (1.48 to 3.95) Total events 40 41 Heterogeneity: *2*0.00; *2*2*0.39, d=2 (p=0.82); P=0% Test for overall effect: Z=3.54 (p=0.0004)  1.2.3 Locoregional recurrence Kawachi 2009 10 41 50 527 3.8% 3.08 (1.42 to 6.65) Okumura 1981 4 22 13 135 2.9% 2.09 (0.61 to 7.10) Saloh 2007 2 41 39 812 2.5% 1.02 (0.24 to 4.36) Shintani 2009 5 67 53 1182 3.4% 1.72 (0.66 to 4.45) Taniguchi 2009 2 14 21 282 2.3% 2.07 (0.43 to 9.87) Subtotal (19% CI) 185 2938 15.0% 2.13 (1.32 to 3.45) Total events *2*0.00; *2*2*0.8, d=4 (p=0.72); P=0% Test for overall effect: Z=3.10 (p=0.002)  1.2.4 Pletural recurrence Bulbr 1997 7 38 5 268 2.9% 11.88 (3.55 to 39.69) Hilgashiyama 1997 7 38 5 5 268 2.9% 11.88 (3.55 to 39.69) Hilgashiyama 2009 21 89 14 590 3.9% 3.05 (1.53 to 713.13) Saloh 2007 8 41 10 812 3.4% 19.44 (7.20 to 52.47) Shintani 2009 3 67 7 1182 2.6% 7.87 (1.99 to 31.14) Skewachi 2009 3 67 7 1182 2.6% 7.87 (1.99 to 31.14) Skuthotal (19% CI) 430 3724 20.5% 9.89 (5.95 to 16.44)  Total events 70 71 Heterogeneity: *2*0.15; *2*8.91, d=6 (p=0.18); P=33% Test for overall effect: Z=8.83 (p=0.00001); P=36% Test for overall effect: Z=3.20 (p=0.001)  1.2.5 Distant recurrence Bulbr 1997 78 132 23 210 4.2% 11.15 (0.54 to 2.44) Kawachi 2009 13 41 69 527 3.9% 3.08 (1.52 to 6.24) Okumura 1991 8 22 34 135 3.5% 2.06 (0.81 to 5.24) Shintani 2009 24 67 324 1182 4.3% 1.48 (0.88 to 2.47) Taniguchi 2009 24 67 324 1182 4.3% 1.48 (0.88 to 2.47) Taniguchi 2009 4 14 27 292 2.9% 3.78 (1.11 to 12.87) Subtotal (19% CI) 355 3416 26.8% 3.18 (1.57 to 6.46)  Total events 524 1916 Heterogeneity: *2*0.76; *2*2*42.18, d=6 (p=0.00001); P=86% Test for overall effect: Z=3.20 (p=0.001)  Total events 524 1916 Heterogeneity: *2*0.76; *2*2*42.18, d=6 (p=0.00001); P=86% Test for overall effect: Z=3.20 (p=0.001)								
Subtota (195% C) 302 688 10.7% 2.42 (1.48 to 3.95) Total events 40 41 Heterogeneity: r²=0.00; r²=0.39, dr=2 (p=0.82); r²=0% Test for overall effect: Z=3.54 (p=0.0004)  1.2.3 Locoregional recurrence Kawachi 2009 10 41 50 527 3.8% 3.08 (1.42 to 6.65) Okumrura 1991 4 22 13 135 2.9% 2.09 (0.61 to 7.10) Saloh 2007 2 41 39 812 2.5% 1.02 (0.24 to 4.36) Shintani 2009 5 14 21 282 2.3% 2.07 (0.43 to 9.87) Subtota (195% C) 185 2938 15.0% 2.13 (1.32 to 3.45)  Total events 23 176 Heterogeneity: r²=0.00; r²=2.08, dr=4 (p=0.7.2); r²=0% Test for overall effect: Z=3.10 (p=0.002)  1.2.4 Pleural recurrence Buhr 1997 22 132 4 210 3.2% 10.30 (3.46 to 30.64) Higashiyama 2009 27 41 31 527 3.6% 3.29 (1.35 to 8.03) Okumura 1991 2 22 0.155 0.9% 33.05 (1.53 to 71.313) Saloh 2007 8 41 10 812 3.4% 19.44 (7.20 to 52.47) Shintani 2009 3 67 7 1182 2.6% 7.87 (1.99 to 31.14) Subtota (195% C) 430 3724 20.5% 9.89 (5.95 to 16.44)  Columnura 1991 2 22 34 135 3.5% 2.08 (1.55 to 73.13) Saloh 2007 8 41 10 812 3.4% 19.44 (7.20 to 52.47) Shintani 2009 3 67 7 1182 2.6% 7.87 (1.99 to 31.14) Subtota (195% C) 430 3724 20.5% 9.89 (5.95 to 16.44)  Total events 40 50 50 50 50 50 50 50 50 50 50 50 50 50								
Total events		18		12				
Heterogeneity: t²=0.00; x²=0.39, df=2 (p=0.82); l²=0% Test for overall effect: Z=3.54 (p=0.0004)  1.2.3 Locoregional recurrence    Kawachi 2009		40	302	- 44	000	10.770	2.42 (1.40 to 3.33)	
Test for overall effect: Z=3.54 (p=0.0004)  1.2.3 Locoregional recurrence  Kawachi 2009 10 41 50 527 3.8% 3.08 (1.42 to 6.65)  Okumura 1991 4 22 13 135 2.9% 2.09 (0.61 to 7.10)  Satoh 2007 2 41 39 812 2.5% 1.02 (0.24 to 4.36)  Shintani 2009 5 67 53 1182 3.4% 1.72 (0.66 to 4.45)  Taniguchi 2009 2 14 21 282 2.3% 2.07 (0.43 to 9.87)  Subtota (195% Cl) 185 2938 15.0% 2.13 (1.32 to 3.45)  Total events 23 176  Heterogeneity: r²=0.00; y²=2.08, df=4 (p=0.72); l²=0%  Test for overall effect: Z=3.10 (p=0.002)  1.2.4 Pleural recurrence  Buhr 1997 7 38 5 268 2.9% 11.88 (3.55 to 39.69)  Higashiyama 1997 7 7 38 5 268 2.9% 11.88 (3.55 to 39.69)  Higashiyama 2009 21 89 14 590 3.9% 12.71 (6.18 to 26.14)  Kawachi 2009 7 41 31 527 3.6% 3.29 (1.35 to 80.3)  Okumura 1991 2 22 0 135 0.9% 33.05 (1.53 to 713.13)  Satoh 2007 8 41 10 812 3.4% 19.44 (7.20 to 52.47)  Shintani 2009 3 67 7 1182 2.6% 7.87 (1.99 to 31.14)  Subtota (195% Cl) 430 3724 20.5% 9.89 (5.95 to 16.44)  Total events 70 71  Heterogeneity: r²=0.15; y²=8.91, df=6 (p=0.18); l²=33%  Test for overall effect: Z=8.83 (p<0.00001)  1.2.5 Distant recurrence  Buhr 1997 7 8 132 23 210 4.2% 11.74 (6.74 to 20.46)  Higashiyama 1997 11 38 70 268 3.9% 1.15 (0.54 to 2.44)  Kawachi 2009 13 41 69 527 3.9% 3.08 (1.52 to 62.47)  Total events 70 71  Heterogeneity: r²=0.15; y²=8.91, df=6 (p=0.18); l²=33%  Test for overall effect: Z=8.83 (p<0.00001)  1.2.5 Distant recurrence  Buhr 1997 78 132 23 210 4.2% 11.74 (6.74 to 20.46)  Higashiyama 1997 11 38 70 268 3.9% 3.08 (1.52 to 6.24)  Satoh 2007 23 41 134 812 4.1% 6.47 (3.40 to 12.31)  Shintani 2009 4 14 27 282 2.9% 3.78 (1.11 to 12.87)  Subtotal (195% Cl) 35 5 3.416 26.8% 3.78 (1.11 to 12.87)  Subtotal (195% Cl) 35 5 3.416 26.8% 3.78 (1.11 to 12.87)  Subtotal (195% Cl) 35 5 3.416 26.8% 3.78 (1.11 to 12.87)  Subtotal (195% Cl) 5.24 2.18, df=6 (p<0.00001); l²=86%  Test for overall effect: Z=3.20 (p=0.0001)  Total events 524 1916  Heterogeneity: r²=0.59; y²=127.18, df=28 p<0.000001); l²=86%			45-0 /		-00/			
1.2.3 Locoregional recurrence  Kawachi 2009 10 41 50 527 3.8% 3.08 (1.42 to 6.65)  Okumura 1991 4 22 13 135 2.9% 2.09 (0.61 to 7.10)  Satoh 2007 2 41 39 812 2.5% 1.02 (0.24 to 4.36)  Shintani 2009 5 67 53 1182 3.4% 1.72 (0.66 to 4.45)  Taniguchi 2009 2 14 21 282 2.3% 2.07 (0.43 to 9.87)  Subtotal (95% C1) 185 2938 15.0% 2.13 (1.32 to 3.45)  Total events 23 176  Heterogeneity: \(\tau^2 = 0.00; \tau^2 = 2.3, 0 \) (p=0.002)  1.2.4 Pleural recurrence  Buhr 1997 22 132 4 210 3.2% 10.30 (3.46 to 30.64)  Higashiyama 1997 7 38 5 268 2.9% 11.88 (3.55 to 39.69)  Higashiyama 2009 21 89 14 590 3.9% 12.71 (6.18 to 26.44)  Kawachi 2009 7 41 31 527 3.6% 3.29 (1.35 to 8.03)  Okumura 1991 2 22 0 135 0.9% 33.05 (1.53 to 713.13)  Satoh 2007 8 41 10 812 2.6% 7.87 (1.99 to 31.14)  Shintani 2009 3 67 7 1182 2.6% 7.87 (1.99 to 31.14)  Shintani 2009 3 67 7 1182 2.6% 7.87 (1.99 to 31.14)  Shintani 2009 3 67 7 1182 2.6% 7.87 (1.99 to 31.14)  Shintani 2009 1 3 41 69 527 3.9% 33.08 (1.52 to 6.24)  Okumura 1991 9 22 34 135 3.5% 2.06 (0.81 to 5.24)  Shintani 2009 1 3 41 69 527 3.9% 3.08 (1.52 to 6.24)  Okumura 1991 9 22 34 135 3.5% 2.06 (0.81 to 5.24)  Satoh 2007 23 41 134 812 4.1% 6.47 (3.40 to 12.31)  Shintani 2009 2 4 67 324 1182 4.3% 1.15 (0.54 to 2.44)  Kawachi 2009 1 3 41 69 527 3.9% 3.08 (1.52 to 6.24)  Okumura 1991 9 22 34 135 3.5% 2.06 (0.81 to 5.24)  Satoh 2007 23 41 134 812 4.1% 6.47 (3.40 to 12.31)  Shintani 2009 4 14 27 282 2.9% 3.78 (1.11 to 12.87)  Subtotal (95% C1) 355 3416 2.68% 3.18 (1.57 to 6.46)  Total events 68  Heterogeneity: \(\tau^2 = 0.76; \tau^2 = 2.12 1.8, \text{ die-6} (p=0.00001); \(\text{ P=86%}\)  Test for overall effect: Z=3.20 (p=0.0001)  Total events 524 1916  Heterogeneity: \(\tau^2 = 0.59; \tau^2 = 2127.18, \text{ die-6} (p=0.00001); \(\text{ P=86%}\)  Test for overall effect: Z=0.59; \(\tau^2 = 2127.18, \text{ die-6} (p=0.00001); \(\text{ P=86%}\)  Test for overall effect: Z=0.59; \(\tau^2 = 2127.18, \text{ die-6} (p=0.00001); \(\text{ P=876}\)			**		=0%			
Kawachi 2009								
Okumura 1991						0.00	0.00 // 10: 0	l
Satch 2007								
Shintani 2009		-						<del>  -</del>
Taniguchi 2009 2 14 21 282 2.3% 2.07 (0.43 to 9.87) Subtotal (95% C1) 185 2938 15.0% 2.13 (1.32 to 3.45) Total events 23 176 Heterogeneity: τ²=0.00; χ²=2.08, df=4 (p=0.72); l²=0% Test for overall effect: Z=3.10 (p=0.002)  1.2.4 Pleural recurrence Buhr 1997 22 132 4 210 3.2% 10.30 (3.46 to 30.64) Higashiyama 1997 7 38 5 268 2.9% 11.88 (3.55 to 39.69) Higashiyama 2009 21 89 14 590 3.9% 12.71 (6.18 to 26.14) Kawachi 2009 7 41 31 527 3.6% 3.29 (1.35 to 8.03) Okumura 1991 2 22 0 135 0.9% 33.05 (1.55 to 713.13) Satoh 2007 8 41 10 812 3.4% 19.44 (7.20 to 52.47) Shintani 2009 3 67 7 1182 2.6% 7.87 (1.99 to 31.14) Subtotal (95% C1) 430 3724 20.5% 9.89 (5.95 to 16.44) Total events 70 71 Heterogeneity: τ²=0.15; χ²=8.91, df=6 (p=0.18); l²=33% Test for overall effect: Z=8.83 (p<0.00001)  1.2.5 Distant recurrence Buhr 1997 78 132 23 210 4.2% 11.74 (6.74 to 20.46) Higashiyama 1997 11 38 70 268 3.9% 3.08 (1.52 to 6.24) Okumura 1991 9 22 34 135 3.5% 2.06 (0.81 to 5.24) Satoh 2007 23 41 134 812 4.1% 6.47 (3.40 to 12.31) Shintani 2009 4 14 27 282 2.9% 3.78 (1.11 to 12.87) Subtotal (95% C1) 355 3416 26.8% Subtotal (95% C1) 1627 14182 100.0% 4.06 (2.91 to 5.65) Total events 162 681 Heterogeneity: τ²=0.59; χ²=127.18, df=28 (p<0.00001); l²=86% Test for overall effect: Z=3.20 (p=0.001); l²=86% Test for overall effect: Z=3.20 (p=0.0001); l								
Subtotal (95% CI) 185 2938 15.0% 2.13 (1.32 to 3.45)  Total events 23 176  Heterogeneity: τ²=0.00; χ²=2.08, df=4 (p=0.72); l²=0%  Test for overall effect: Z=3.10 (p=0.002)  1.2.4 Pleural recurrence  Buhr 1997 22 132 4 210 3.2% 10.30 (3.46 to 30.64)  Higashiyama 1997 7 38 5 268 2.9% 11.88 (3.55 to 39.69)  Higashiyama 2009 21 89 14 590 3.9% 12.71 (6.18 to 26.14)  Kawachi 2009 7 41 31 527 3.6% 3.29 (1.35 to 8.03)  Okumura 1991 2 22 0 135 0.9% 33.05 (1.53 to 713.13)  Satoh 2007 8 41 10 812 3.4% 19.44 (7.20 to 52.47)  Shintani 2009 3 67 7 1182 2.6% 7.87 (1.99 to 31.14)  Subtotal (95% CI) 430 3724 20.5% 9.89 (5.95 to 16.44)  Total events 70 71  Heterogeneity: τ²=0.15; χ²=8.91, df=6 (p=0.18); l²=33%  Test for overall effect: Z=8.83 (p<0.00001)  1.2.5 Distant recurrence  Buhr 1997 78 132 23 210 4.2% 11.74 (6.74 to 20.46)  Higashiyama 1997 11 38 70 268 3.9% 1.15 (0.54 to 2.44)  Kawachi 2009 13 41 69 527 3.9% 3.08 (1.52 to 6.24)  Okumura 1991 9 22 34 133 3.5% 2.06 (0.81 to 5.24)  Satoh 2007 23 41 134 812 4.1% 6.47 (3.40 to 12.31)  Shintani 2009 24 67 324 1182 4.3% 1.48 (0.88 to 2.47)  Taniguchi 2009 24 14 27 282 2.9% 3.78 (1.11 to 12.87)  Subtotal (95% CI) 355 3416 26.8% 3.8 (1.157 to 6.46)  Total events 162 681  Heterogeneity: τ²=0.75; χ²=127.18, df=28 (p<0.00001); l²=86%  Test for overall effect: Z=3.20 (p=0.0011)  Total (95% CI) 1627 14182 100.0% 4.06 (2.91 to 5.65)  Total events 524 1916  Heterogeneity: τ²=0.59; χ²=127.18, df=28 (p<0.00001); l²=78%							,	<del></del>
Heterogeneity: \$z^2=0.00; \$\chi^2=2.08\$, df=4 (p=0.72);  z^2=0%\$ Test for overall effect: \$Z=3.10 (p=0.002)\$  1.2.4 Pleural recurrence  Buhr 1997	Taniguchi 2009 Subtotal (95% CI)	2		21				•
Test for overall effect: Z=3.10 (p=0.002)  1.2.4 Pleural recurrence  Buhr 1997	Total events	23		176				
Test for overall effect: Z=3.10 (p=0.002)  1.2.4 Pleural recurrence  Buhr 1997		$\gamma^2 = 2.08$	df=4 (p	=0.72); I <sup>2</sup> =	=0%			
Buhr 1997				··· =/, ·				
Higashiyama 1997 7 38 5 268 2.9% 11.88 (3.55 to 39.69) Higashiyama 2009 21 89 14 590 3.9% 12.71 (6.18 to 26.14) Kawachi 2009 7 41 31 527 3.6% 3.29 (1.35 to 8.03) Okumura 1991 2 22 0 135 0.9% 33.05 (1.53 to 713.13) Satoh 2007 8 41 10 812 3.4% 19.44 (7.20 to 52.47) Shintani 2009 3 67 7 1182 2.6% 7.87 (1.99 to 31.14) Subtotal (95% CI) 430 3724 20.5% 9.89 (5.95 to 16.44) Total events 70 71 Heterogeneity: \(\tau^2 = 0.15\); \(\chi^2 = 8.91\), \(\deta = 6\) (\(\rho = 0.18\)); \(\rho^2 = 33\)% Test for overall effect: \(\mathbb{Z} = 8.83\) (\(\rho = 0.00001)\)  1.2.5 Distant recurrence  Buhr 1997 78 132 23 210 4.2% 11.74 (6.74 to 20.46) Higashiyama 1997 11 38 70 268 3.9% 1.15 (0.54 to 2.44) Kawachi 2009 13 41 69 527 3.9% 3.08 (1.52 to 6.24) Okumura 1991 9 22 34 135 3.5% 2.06 (0.81 to 5.24) Satoh 2007 23 41 134 812 4.1% 6.47 (3.40 to 12.31) Shintani 2009 24 67 324 1182 4.3% 1.48 (0.88 to 2.47) Taniguchi 2009 4 14 27 282 2.9% 3.78 (1.11 to 12.87) Subtotal (95% CI) 355 3416 26.8% 3.18 (1.57 to 6.46) Total events 162 681 Heterogeneity: \(\tau^2 = 0.76\); \(\chi^2 = 24.218\), \(\deta = 6\) (\(\rho = 0.00001)\); \(\rho = 86\) Test for overall effect: \(\mathbb{Z} = 3.20\) (\(\rho = 0.00001)\); \(\rho = 86\) Total events 524 1916 Heterogeneity: \(\tau^2 = 0.59\); \(\chi^2 = 21.7.18\), \(\deta = 28\) (\(\rho = 0.00001)\); \(\rho = 7.88\)	1.2.4 Pleural recurrence	ce						
Higashiyama 1997 7 38 5 268 2.9% 11.88 (3.55 to 39.69) Higashiyama 2009 21 89 14 590 3.9% 12.71 (6.18 to 26.14) Kawachi 2009 7 41 31 527 3.6% 3.29 (1.35 to 8.03) Okumura 1991 2 22 0 135 0.9% 33.05 (1.53 to 713.13) Satoh 2007 8 41 10 812 3.4% 19.44 (7.20 to 52.47) Shintani 2009 3 67 7 1182 2.6% 7.87 (1.99 to 31.14) Subtotal (95% CI) 430 3724 20.5% 9.89 (5.95 to 16.44) Total events 70 71 Heterogeneity: \(\tau^2 = 0.15\); \(\chi^2 = 8.91\), \(\deta = 6\) (\(\rho = 0.18\)); \(\rho^2 = 33\)% Test for overall effect: \(\mathbb{Z} = 8.83\) (\(\rho = 0.00001)\)  1.2.5 Distant recurrence  Buhr 1997 78 132 23 210 4.2% 11.74 (6.74 to 20.46) Higashiyama 1997 11 38 70 268 3.9% 1.15 (0.54 to 2.44) Kawachi 2009 13 41 69 527 3.9% 3.08 (1.52 to 6.24) Okumura 1991 9 22 34 135 3.5% 2.06 (0.81 to 5.24) Satoh 2007 23 41 134 812 4.1% 6.47 (3.40 to 12.31) Shintani 2009 24 67 324 1182 4.3% 1.48 (0.88 to 2.47) Taniguchi 2009 4 14 27 282 2.9% 3.78 (1.11 to 12.87) Subtotal (95% CI) 355 3416 26.8% 3.18 (1.57 to 6.46) Total events 162 681 Heterogeneity: \(\tau^2 = 0.76\); \(\chi^2 = 24.218\), \(\deta = 6\) (\(\rho = 0.00001)\); \(\rho = 86\) Test for overall effect: \(\mathbb{Z} = 3.20\) (\(\rho = 0.00001)\); \(\rho = 86\) Total events 524 1916 Heterogeneity: \(\tau^2 = 0.59\); \(\chi^2 = 21.7.18\), \(\deta = 28\) (\(\rho = 0.00001)\); \(\rho = 7.88\)	Buhr 1997	22	132	4	210	3 2%	10.30 (3.46 to 30.64)	
Higashiyama 2009 21 89 14 590 3.9% 12.71 (6.18 to 26.14) Kawachi 2009 7 41 31 527 3.6% 3.29 (1.35 to 8.03) Okumura 1991 2 22 0 135 0.9% 33.05 (1.53 to 713.13) Satoh 2007 8 41 10 812 3.4% 19.44 (7.20 to 52.47) Shintani 2009 3 67 7 1182 2.6% 7.87 (1.99 to 31.14) Subtotal (95% CI) 430 3724 20.5% 9.89 (5.95 to 16.44) Total events 70 71 Heterogeneity: \(\tau^2 = 0.15; \chi^2 = 8.91, \text{ df=6 (p=0.18); } \(\text{ l}^2 = 33\)\text{ Test for overall effect: Z=8.83 (p<0.00001)}  1.2.5 Distant recurrence Buhr 1997 78 132 23 210 4.2% 11.74 (6.74 to 20.46) Higashiyama 1997 11 38 70 268 3.9% 1.15 (0.54 to 2.44) Kawachi 2009 13 41 69 527 3.9% 3.08 (1.52 to 6.24) Okumura 1991 9 22 34 135 3.5% 2.06 (0.81 to 5.24) Satoh 2007 23 41 134 812 4.1% 6.47 (3.40 to 12.31) Shintani 2009 24 67 324 1182 4.3% 1.48 (0.88 to 2.47) Taniguchi 2009 4 14 27 282 2.9% 3.78 (1.11 to 12.87) Subtotal (95% CI) 355 3416 26.8% 3.18 (1.57 to 6.46) Total events 162 681 Heterogeneity: \(\tau^2 = 0.76; \chi^2 = 42.18, \text{ df=6 (p<0.00001); } \text{ l}^2 = 86\) Test for overall effect: Z=3.20 (p=0.001)  Total (95% CI) 1627 14182 100.0% 4.06 (2.91 to 5.65)  Total events 524 1916 Heterogeneity: \(\tau^2 = 0.59; \chi^2 = 12.7.18, \text{ df=28 (p<0.00001); } \text{ l}^2 = 78\)								
Kawachi 2009	<del></del>							
Okumura 1991								l ——
Satoh 2007 8 41 10 812 3.4% 19.44 (7.20 to 52.47) Shintani 2009 3 67 7 1182 2.6% 7.87 (1.99 to 31.14) Subtotal (95% CI) 430 3724 20.5% 9.89 (5.95 to 16.44)  Total events 70 71 Heterogeneity: τ²=0.15; χ²=8.91, df=6 (p=0.18); l²=33%  Test for overall effect: Z=8.83 (p<0.00001)  1.2.5 Distant recurrence  Buhr 1997 78 132 23 210 4.2% 11.74 (6.74 to 20.46) Higashiyama 1997 11 38 70 268 3.9% 1.15 (0.54 to 2.44) Kawachi 2009 13 41 69 527 3.9% 3.08 (1.52 to 6.24) Okumura 1991 9 22 34 135 3.5% 2.06 (0.81 to 5.24) Satoh 2007 23 41 134 812 4.1% 6.47 (3.40 to 12.31) Shintani 2009 24 67 324 1182 4.3% 1.48 (0.88 to 2.47) Taniguchi 2009 4 14 27 282 2.9% 3.78 (1.11 to 12.87) Subtotal (95% CI) 355 3416 26.8% 3.18 (1.57 to 6.46)  Total events 162 681 Heterogeneity: τ²=0.76; χ²=42.18, df=6 (p<0.00001); l²=86%  Test for overall effect: Z=3.20 (p=0.001)  Total (95% CI) 1627 14182 100.0% 4.06 (2.91 to 5.65)  Total events 524 1916 Heterogeneity: τ²=0.59; χ²=127.18, df=28 (p<0.00001); l²=78%								
Shintani 2009 3 67 7 1182 2.6% 7.87 (1.99 to 31.14) Subtotal (95% CI) 430 3724 20.5% 9.89 (5.95 to 16.44)  Total events 70 71  Heterogeneity: τ²=0.15; χ²=8.91, df=6 (p=0.18); l²=33%  Test for overall effect: Z=8.83 (p<0.00001)  1.2.5 Distant recurrence  Buhr 1997 78 132 23 210 4.2% 11.74 (6.74 to 20.46)  Higashiyama 1997 11 38 70 268 3.9% 1.15 (0.54 to 2.44)  Kawachi 2009 13 41 69 527 3.9% 3.08 (1.52 to 6.24)  Okumura 1991 9 22 34 135 3.5% 2.06 (0.81 to 5.24)  Satoh 2007 23 41 134 812 4.1% 6.47 (3.40 to 12.31)  Shintani 2009 24 67 324 1182 4.3% 1.48 (0.88 to 2.47)  Taniguchi 2009 4 14 27 282 2.9% 3.78 (1.11 to 12.87)  Subtotal (95% CI) 355 3416 26.8% 3.18 (1.57 to 6.46)  Total events 162 681  Heterogeneity: τ²=0.76; χ²=42.18, df=6 (p<0.00001); l²=86%  Test for overall effect: Z=3.20 (p=0.001)  Total (95% CI) 1627 14182 100.0% 4.06 (2.91 to 5.65)  Total events 524 1916  Heterogeneity: τ²=0.59; χ²=127.18, df=28 (p<0.00001); l²=78%								
Subtotal (95% CI) 430 3724 20.5% 9.89 (5.95 to 16.44)  Total events 70 71  Heterogeneity: \(\tau^2 = 0.15\); \(\chi^2 = 8.91\), \(d=6\) (\(\rho = 0.18\); \(l^2 = 33\)%  Test for overall effect: \(Z=8.83\) (\(\rho < 0.00001\))  1.2.5 Distant recurrence  Buhr 1997 78 132 23 210 4.2% 11.74 (6.74 to 20.46)  Higashiyama 1997 11 38 70 268 3.9% 1.15 (0.54 to 2.44)  Kawachi 2009 13 41 69 527 3.9% 3.08 (1.52 to 6.24)  Okumura 1991 9 22 34 135 3.5% 2.06 (0.81 to 5.24)  Satoh 2007 23 41 134 812 4.1% 6.47 (3.40 to 12.31)  Shintani 2009 24 67 324 1182 4.3% 1.48 (0.88 to 2.47)  Taniguchi 2009 4 14 27 282 2.9% 3.78 (1.11 to 12.87)  Subtotal (95% CI) 355 3416 26.8% 3.18 (1.57 to 6.46)  Total events 162 681  Heterogeneity: \(\tau^2 = 0.76\); \(\chi^2 = 42.18\), \(d=6\) (\(\rho < 0.00001\)); \(l^2 = 86\)%  Test for overall effect: \(Z=3.20\) (\(\rho = 0.0001\)); \(l^2 = 86\)%  Total events 524 1916  Heterogeneity: \(\tau^2 = 0.59\); \(\chi^2 = 12.7.18\), \(d=28\) (\(\rho < 0.00001\)); \(l^2 = 78\)%  Heterogeneity: \(\tau^2 = 0.59\); \(\chi^2 = 12.7.18\), \(d=28\) (\(\rho < 0.00001\)); \(l^2 = 78\)%								l ———
Total events 70 71 Heterogeneity: τ²=0.15; χ²=8.91, df=6 (p=0.18); l²=33% Test for overall effect: Z=8.83 (p<0.00001)  1.2.5 Distant recurrence  Buhr 1997 78 132 23 210 4.2% 11.74 (6.74 to 20.46) Higashiyama 1997 11 38 70 268 3.9% 1.15 (0.54 to 2.44) Kawachi 2009 13 41 69 527 3.9% 3.08 (1.52 to 6.24) Okumura 1991 9 22 34 135 3.5% 2.06 (0.81 to 5.24) Satoh 2007 23 41 134 812 4.1% 6.47 (3.40 to 12.31) Shintani 2009 24 67 324 1182 4.3% 1.48 (0.88 to 2.47) Taniguchi 2009 4 14 27 282 2.9% 3.78 (1.11 to 12.87) Subtotal (95% CI) 355 3416 26.8% 3.18 (1.57 to 6.46) Total events 162 681 Heterogeneity: τ²=0.76; χ²=42.18, df=6 (p<0.00001); l²=86% Test for overall effect: Z=3.20 (p=0.001)  Total (95% CI) 1627 14182 100.0% 4.06 (2.91 to 5.65) Total events 524 1916 Heterogeneity: τ²=0.59; χ²=127.18, df=28 (p<0.00001); l²=78%		3		,				•
Heterogeneity: $\tau^2$ =0.15; $\chi^2$ =8.91, df=6 (p=0.18); l²=33% Test for overall effect: Z=8.83 (p<0.00001)  1.2.5 Distant recurrence  Buhr 1997		70		71			( 10)	
Test for overall effect: Z=8.83 (p<0.00001)  1.2.5 Distant recurrence  Buhr 1997			df=6 (n		-33%			
Buhr 1997 78 132 23 210 4.2% 11.74 (6.74 to 20.46) Higashiyama 1997 11 38 70 268 3.9% 1.15 (0.54 to 2.44) Kawachi 2009 13 41 69 527 3.9% 3.08 (1.52 to 6.24) Okumura 1991 9 22 34 135 3.5% 2.06 (0.81 to 5.24) Satoh 2007 23 41 134 812 4.1% 6.47 (3.40 to 12.31) Shintani 2009 24 67 324 1182 4.3% 1.48 (0.88 to 2.47) Taniguchi 2009 4 14 27 282 2.9% 3.78 (1.11 to 12.87) Subtotal (95% CI) 355 3416 26.8% 3.18 (1.57 to 6.46) Total events 162 681 Heterogeneity: \(\tau^2 = 0.76; \(\chi^2 = 42.18, \) df=6 \((\text{(p<0.00001)}; \) \(\text{i}^2 = 86\) Total (95% CI) 1627 14182 100.0% 4.06 (2.91 to 5.65) Total events 524 1916 Heterogeneity: \(\tau^2 = 0.59; \(\chi^2 = 12.7.18, \) df=28 \((\text{(p<0.00001)}; \) \(\text{i}^2 = 78\) Heterogeneity: \(\tau^2 = 0.59; \(\chi^2 = 12.7.18, \) df=28 \((\text{(p<0.00001)}; \) \(\text{i}^2 = 78\)					-55 /6			
Buhr 1997 78 132 23 210 4.2% 11.74 (6.74 to 20.46) Higashiyama 1997 11 38 70 268 3.9% 1.15 (0.54 to 2.44) Kawachi 2009 13 41 69 527 3.9% 3.08 (1.52 to 6.24) Okumura 1991 9 22 34 135 3.5% 2.06 (0.81 to 5.24) Satoh 2007 23 41 134 812 4.1% 6.47 (3.40 to 12.31) Shintani 2009 24 67 324 1182 4.3% 1.48 (0.88 to 2.47) Taniguchi 2009 4 14 27 282 2.9% 3.78 (1.11 to 12.87) Subtotal (95% CI) 355 3416 26.8% 3.18 (1.57 to 6.46) Total events 162 681 Heterogeneity: \(\tau^2 = 0.76; \(\chi^2 = 42.18, \) df=6 \((\text{(p<0.00001)}; \) \(\text{i}^2 = 86\) Total (95% CI) 1627 14182 100.0% 4.06 (2.91 to 5.65) Total events 524 1916 Heterogeneity: \(\tau^2 = 0.59; \(\chi^2 = 12.7.18, \) df=28 \((\text{(p<0.00001)}; \) \(\text{i}^2 = 78\) Heterogeneity: \(\tau^2 = 0.59; \(\chi^2 = 12.7.18, \) df=28 \((\text{(p<0.00001)}; \) \(\text{i}^2 = 78\)	1.2.5 Distant recurrence	ce						
Higashiyama 1997 11 38 70 268 3.9% 1.15 (0.54 to 2.44)  Kawachi 2009 13 41 69 527 3.9% 3.08 (1.52 to 6.24)  Okumura 1991 9 22 34 135 3.5% 2.06 (0.81 to 5.24)  Satoh 2007 23 41 134 812 4.1% 6.47 (3.40 to 12.31)  Shintani 2009 24 67 324 1182 4.3% 1.48 (0.88 to 2.47)  Taniguchi 2009 4 14 27 282 2.9% 3.78 (1.11 to 12.87)  Subtotal (95% CI) 355 3416 26.8% 3.18 (1.57 to 6.46)  Total events 162 681  Heterogeneity: τ²=0.76; χ²=42.18, df=6 (p<0.00001); l²=86%  Test for overall effect: Z=3.20 (p=0.001)  Total (95% CI) 1627 14182 100.0% 4.06 (2.91 to 5.65)  Total events 524 1916  Heterogeneity: τ²=0.59; χ²=127.18, df=28 (p<0.00001); l²=78%			122	22	210	1 204	11 74 (6 74 to 20 46)	
Kawachi 2009   13								
Okumura 1991 9 22 34 135 3.5% 2.06 (0.81 to 5.24) Satoh 2007 23 41 134 812 4.1% 6.47 (3.40 to 12.31) Shintani 2009 24 67 324 1182 4.3% 1.48 (0.88 to 2.47) Taniguchi 2009 4 14 27 282 2.9% 3.78 (1.11 to 12.87) Subtotal (95% CI) 355 3416 26.8% 3.18 (1.57 to 6.46) Total events 162 681 Heterogeneity: \(\tau^2 = 0.76\); \(\tau^2 = 42.18\), \(d=6\) (p<0.00001); \(\tau^2 = 86\) Total (95% CI) 1627 14182 100.0% 4.06 (2.91 to 5.65) Total events 524 1916 Heterogeneity: \(\tau^2 = 0.59\); \(\tau^2 = 127.18\), \(d=28\) (p<0.00001); \(\tau^2 = 78\) Heterogeneity: \(\tau^2 = 0.59\); \(\tau^2 = 127.18\), \(d=28\) (p<0.00001); \(\tau^2 = 78\)							· ·	l
Satch 2007 23 41 134 812 4.1% 6.47 (3.40 to 12.31) Shintani 2009 24 67 324 1182 4.3% 1.48 (0.88 to 2.47) Taniguchi 2009 4 14 27 282 2.9% 3.78 (1.11 to 12.87) Sulbtotal (95% CI) 355 3416 26.8% 3.18 (1.57 to 6.46) Total events 162 681 Heterogeneity: \(\tau^2 = 0.76; \chi^2 = 42.18, \text{ df=6 } (p<0.00001); \(\text{ l}^2 = 86\times \) Total (95% CI) 1627 14182 100.0% 4.06 (2.91 to 5.65) Total events 524 1916 Heterogeneity: \(\tau^2 = 0.59; \chi^2 = 127.18, \text{ df=28 } (p<0.00001); \(\text{ l}^2 = 78\times \)							,	
Shintani 2009 24 67 324 1182 4.3% 1.48 (0.88 to 2.47) Taniguchi 2009 4 14 27 282 2.9% 3.78 (1.11 to 12.87) Sulbtotal (95% CI) 355 3416 26.8% 3.18 (1.57 to 6.46)  Total events 162 681 Heterogeneity: \(\tau^2 = 0.76; \chi^2 = 42.18, \text{ df=6 } (\rho < 0.00001); \(\text{ l}^2 = 86\times \text{ Total (95\times CI)} \)  101 1627 14182 100.0% 4.06 (2.91 to 5.65)  Total events 524 1916 Heterogeneity: \(\tau^2 = 0.59; \chi^2 = 127.18, \text{ df=28 } (\rho < 0.00001); \(\text{ l}^2 = 78\times \text{ 15 20} \)		_						
Taniguchi 2009 4 14 27 282 2.9% 3.78 (1.11 to 12.87) Sulbtotal (95% CI) 355 3416 26.8% 3.18 (1.57 to 6.46)  Total events 162 681  Heterogeneity: \(\tau^2 = 0.76\); \(\tau^2 = 42.18\), \(\text{df} = 6\) (p<0.00001); \(\text{l}^2 = 86\)  Total (95% CI) 1627 14182 100.0% 4.06 (2.91 to 5.65)  Total events 524 1916  Heterogeneity: \(\tau^2 = 0.59\); \(\tau^2 = 127.18\), \(\text{df} = 28\) (p<0.00001); \(\text{l}^2 = 78\)  Heterogeneity: \(\tau^2 = 0.59\); \(\tau^2 = 127.18\), \(\text{df} = 28\) (p<0.00001); \(\text{l}^2 = 78\)								
Subtotal (95% CI) 355 3416 26.8% 3.18 (1.57 to 6.46)  Total events 162 681  Heterogeneity: \(\tau^2 = 0.76; \chi^2 = 42.18, \) df=6 (p<0.00001); \(\text{l}^2 = 86\)  Total (95\) CI) 1627 14182 100.0\(\text{m}\) 4.06 (2.91 to 5.65)  Total events 524 1916  Heterogeneity: \(\tau^2 = 0.59; \chi^2 = 127.18, \) df=28 (p<0.00001); \(\text{l}^2 = 78\)  Heterogeneity: \(\tau^2 = 0.59; \chi^2 = 127.18, \) df=28 (p<0.00001); \(\text{l}^2 = 78\)								
Total events 162 681 Heterogeneity: $\tau^2$ =0.76; $\chi^2$ =42.18, df=6 (p<0.00001); l²=86% Test for overall effect: Z=3.20 (p=0.001)  Total (95% CI) 1627 14182 100.0% 4.06 (2.91 to 5.65)  Total events 524 1916 Heterogeneity: $\tau^2$ =0.59; $\chi^2$ =127.18, df=28 (p<0.00001); l²=78% 0.05 0.2 1 5 20		4		27			,	
Heterogeneity: $\tau^2$ =0.76; $\chi^2$ =42.18, df=6 (p<0.00001); l <sup>2</sup> =86% Test for overall effect: Z=3.20 (p=0.001)    Total (95% CI)		462	333	601	3410	20.8%	3.18 (1.57 to 6.46)	
Total (95% CI) 1627 14182 100.0% 4.06 (2.91 to 5.65)  Total events 524 1916  Heterogeneity: \(\tau^2 = 0.59\); \(\chi^2 = 127.18\), \(d=28\) (p<0.00001); \(l^2 = 78\)  15 20			46-0		11. 12-00	0/		
Total events 524 1916 Heterogeneity: $\tau^2$ =0.59; $\chi^2$ =127.18, df=28 (p<0.00001); l <sup>2</sup> =78% 0.05 0.2 1 5 20				p<0.0000	1); I=86	%		
Total events 524 1916 Heterogeneity: $\tau^2$ =0.59; $\chi^2$ =127.18, df=28 (p<0.00001); l <sup>2</sup> =78% 0.05 0.2 1 5 20		***			14402	100.00	4.06 /2.04 1- 5.05	
Heterogeneity: $\tau^2$ =0.59; $\chi^2$ =127.18, df=28 (p<0.00001); l²=78% 0.05 0.2 1 5 20			1027	4046	14182	100.0%	4.06 (2.91 to 5.65)	-
0.05 0.2 1 5 20			0		004) 10	700/		
		,,		"	001); I <sup>2</sup> =	18%		
	Test for overall effect: Z	=8.28 (p<	0.0000	1)				

3.18 (95% CI 1.57 to 6.46;  $\chi^2$  of heterogeneity 42.25 (p<0.00001)). <sup>3 9-11 24 25 34</sup>

# Meta-analysis of maximum follow-up survival data

Survival: pathological stage I—IV

In 11 of the 17 studies, <sup>8</sup>  $^{11-13}$   $^{24}$   $^{25}$   $^{27}$   $^{28}$   $^{31}$   $^{32}$   $^{34}$  the association between positive pre-resection PLC and unfavourable survival outcome (all stages) in comparison to negative pre-resection PLC was statistically significant. A meta-analysis of all 17 studies (706 patients (7.14%) had positive pre-resection PLC) at maximum follow-up supported this finding, with a statistically significant pooled HR of 2.08 (95% CI 1.71 to 2.52;  $\chi^2$  of heterogeneity 54.63 (p<0.00001)) (figure 3).

# Survival: pathological stage I

Nine studies reported survival data for patients with stage I only. Solution 19 12 24–27 31 32 Analysis suggested that the association between positive pre-resection PLC and a poor survival outcome was even more pronounced in this group. HR was of statistical significance at 4.20 (random-effects model; 95% CI 2.65 to 6.65;  $\chi^2$  of heterogeneity 17.90 (p<0.02)).

## Sensitivity analysis (overall recurrence)

#### Study size (>350 patients)

Of the seven studies reporting overall recurrence, three followed up more than 350 patients.  $^{3}$   $^{10}$   $^{11}$  The OR of these three studies (149 patients (5.58%) had positive pre-resection PLC) was of statistical significance at 4.40 (95% CI 1.52 to 12.73).

## Positive PLC percentage

Of the seven studies reporting overall recurrence, PLC was positive for <5% of the total participants in two studies (55 patients, 4.79%). The OR was of statistical significance at 10.01 (95% CI 5.09 to 19.69). Similarly, PLC was positive for 5–10% of the total participants also in two studies (108 patients, 5.94%): OR was of statistical significance at 2.62 (95% CI 1.31 to 5.24). In Finally, two studies (60 patients, 13.0%) are reported 10–20% of the total participants had positive PLC with similar results. The OR was of statistical significance at 2.65 (95% CI 1.45 to 4.85).

# Quality assessment

Of the seven studies reporting recurrence, four studies<sup>3</sup> 10 24 25 were of high quality (>11 matched factors) and were analysed

separately. Two hundred and seventy-eight patients (10.1%) had positive pre-resection PLC. The OR was 5.07 (95% CI 1.70 to 15.19).

The results of the meta-regression are summarised in table 2. A sensitivity analysis of the survival data is shown in online appendix D, with an overall results summary presented in table 3.

## **Publication bias**

Figure 4 is a funnel plot including all studies (overall recurrence) and reveals four studies  $^{3}$   $^{10}$   $^{24}$   $^{25}$  lying outside the 95% CI. After exclusion of these outliers, the recurrence outcomes for all patients (OR 4.25; 95% CI 2.61 to 6.92) and hence our conclusions, were not altered significantly.

# **DISCUSSION**

Previous reports have highlighted the prognostic importance of PLC with regards to survival. However, there has been no qualitative assessment of the relationship between positive PLC and lung cancer recurrence. A meta-analysis of the eight studies reporting recurrence rates identified an association between positive pre-resection PLC findings and overall, pleural and distant recurrence (statistically significant ORs of 4.82 (95% CI 2.45 to 9.51), 9.89 (95% CI 5.95 to 16.44) and 3.18 (95% CI 1.56 to 6.46), respectively). This pattern was further demonstrated when analysing local and loco-regional recurrence rates. As predicted, positive pre-resection PLC was also strongly associated with poor survival outcomes with an HR of 2.08 (95% CI 1.71 to 2.52). With respect to survival outcomes, patients with stage I disease are of particular importance because the mainstay of their treatment is surgical resection. On analysis of studies which reported survival data for patients with stage I disease only, the association between the presence of positive PLC and unfavourable survival outcomes was even more pronounced (HR 4.20; 95% CI 2.65 to 6.65).

The results of this meta-analysis allow us to generate a clinical hypothesis: PLC may be a significant adverse prognostic predictor for recurrence (and survival) in patients with (early stage) lung cancer awaiting operative lung resection who may benefit from additional systemic treatment. Our meta-analysis focused on pre-resection PLC only because we wished to test its potential as an additional investigational tool. The point is that by performing PLC prior to surgery, clinicians can use the information to create a more accurate and detailed management

**Figure 3** Forest plot comparing survival outcomes: 'positive PLC versus negative PLC' (all patients). PLC, pleural lavage cytology.

			Positive	Negative		HR	HR		
Study	log(Hazard Ratio)	SE	Total	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI		
1.1.1 Survival - maximum follow-up									
Aokage 2010	0.85	0.16	65	2113	8.1%	2.34 (1.71 to 3.20)			
Buhr 1997	0.84	0.13	132	210	8.7%	2.32 (1.80 to 2.99)	_		
Dresler 1999	0.73	0.28	17	113	5.6%	2.08 (1.20 to 3.59)			
Higashiyama 1997	0.29	0.26	38	268	6.0%	1.34 (0.80 to 2.22)	+		
Higashiyama 2009	0.51	0.16	89	590	8.1%	1.67 (1.22 to 2.28)			
Hillerdal 1998	0.65	0.42	17	121	3.6%	1.92 (0.84 to 4.36)	+		
Kawachi 2009	1.09	0.08	41	527	9.6%	2.97 (2.54 to 3.48)	-		
Kondo 1993	1.2	0.16	42	425	8.1%	3.32 (2.43 to 4.54)			
Lim 2004	1.17	0.27	13	279	5.8%	3.22 (1.90 to 5.47)			
Nakagawa 2007	1.23	0.51	27	977	2.8%	3.42 (1.26 to 9.30)			
Okada 2003	0.49	0.23	45	955	6.6%	1.63 (1.04 to 2.56)			
Okumura 1991	0.89	0.32	23	135	4.9%	2.44 (1.30 to 4.56)			
Satoh 2007	0.22	0.22	41	812	6.8%	1.25 (0.81 to 1.92)	+-		
Shintani 2009	0.07	0.18	67	1182	7.6%	1.07 (0.75 to 1.53)	+		
Taniguchi 2009	0.69	0.61	14	282	2.1%	1.99 (0.60 to 6.59)	<del></del>		
Tomita 2005	0.84	0.59	16	134	2.2%	2.32 (0.73 to 7.36)	+		
Vicidomini 2005	0.96	0.43	19	65	3.5%	2.61 (1.12 to 6.07)			
Subtotal (95% CI)			706	9188	100.0%	2.08 (1.71 to 2.52)	•		
Heterogeneity: $\tau^2=0$ .	10; χ <sup>2</sup> =54.63, df=16	p<0.0	00001); I <sup>2</sup> :	=71%					
Test for overall effect	et: Z=7.37 (p<0.00001	)	- 50						
Total (95% CI)			706	9188	100.0%	2.08 (1.71 to 2.52)	•		
Heterogeneity: τ <sup>2</sup> =0.	.10; χ <sup>2</sup> =54.63, df=16	p<0.0	00001); 12:	=71%			-tttt		
	et: Z=7.37 (p<0.00001		,,				0.1 0.2 0.5 1 2 5 10		

Table 2 Meta-regression analysis of recurrence data: weighted least squares model

Moderators	Coefficient (95% CI)	p Value	
Overall recurrence			
Study quality	0.05 (-0.13 to 0.24)	0.49	
Publication year	-0.01 (-0.08 to 0.50)	0.63	
Number of patients	-0.00 ( $-0.001$ to 0.001)	0.43	
Gender (male)	-0.00 ( $-0.003$ to $0.001$ )	0.16	
+PLC <5%	0.42 (-0.42 to 1.27)	0.25	
+PLC 5-10%	-0.47 (-1.12 to 0.18)	0.12	
+PLC 10-20%	-0.34 (-1.28 to 0.60)	0.40	
+PLC >20%	0.54 (-0.25 to 1.32)	0.14	
Pleural recurrence			
Study quality	0.11 (0.03 to 0.20)	0.02	
Publication year	-0.01 ( $-0.07$ to 0.04)	0.55	
Number of patients	0.00 (-0.001 to 0.001)	0.84	
Gender (male)	-0.19 (-1.43 to 1.05)	0.71	
+PLC <5%	0.35 (-0.36 to 1.07)	0.26	
+PLC 5-10%	-0.51 (-0.84 to 0.17)	0.01	
+PLC 10-20%	0.21 (-0.35 to 0.77)	0.38	
+PLC > 20%	0.03 (-0.87 to 0.92)	0.95	
Distant recurrence			
Study quality	0.05 (-0.15 to 0.24)	0.56	
Publication year	-0.01 (-0.07 to 0.05)	0.67	
Number of patients	0.00 (-0.001 to 0.001)	0.44	
Gender (male)	0.75 (-0.46 to 1.95)	0.17	
+PLC < 5%	0.22 (-0.57 to 1.00)	0.51	
+PLC 5-10%	-0.39 (-1.11 to 0.33)	0.22	
+PLC 10-20%	-0.45 (-1.40 to 0.49)	0.27	
+PLC>20%	0.64 (-0.06 to 1.34)	0.07	

PLC, pleural lavage cytology.


plan than would be possible if PLC was not done. This is because this information will have an impact on whether (or not) to administer chemotherapy and subsequent surgical indications.

Although it is not possible to determine if the relationship between lung cancer cell detection and disease recurrence is causal or simply associative, the detection of lung cancer cells can reflect the presence of extrapleural spread at the time of surgery that might have been missed when using conventional techniques. A significant proportion of patients with stage I cancers and without macroscopic pleural involvement had

**Table 3** Summary of the performed meta-analyses (random-effects model)

Meta-analysis	HR/OR (95% CI)	l² (%)	Degree of heterogeneity
Overall analysis (recurrence)			
Recurrence (overall)	OR 4.82 (2.45 to 9.51)	85	High
Recurrence (local)	OR 2.42 (1.48 to 3.95)	0	Low
Recurrence (loco-regional)	OR 2.13 (1.32 to 3.45)	0	Low
Recurrence (pleural)	OR 9.89 (5.95 to 16.44)	33	Moderate
Recurrence (distant)	OR 3.18 (1.56 to 6.46)	86	High
Overall analysis (survival)			
Total follow-up (all studies)	HR 2.08 (1.71 to 2.52)	71	Moderate
Total follow-up (stage I)	HR 4.20 (2.65 to 6.65)	55	Moderate
Subgroup analysis (overall recu	rrence)		
Study size (>350 patients)	OR 4.40 (1.52 to 12.73)	88	High
Positive PLC % (<5%)	OR 10.01 (5.09 to 19.69)	11	Low
Study score (high quality)	OR 5.07 (1.70 to 15.19)	82	High
Subgroup analysis (survival)			
Study score (high quality)	HR 1.74 (1.37 to 2.23)	71	Moderate

Please note, the degree of heterogeneity was graded as low (I $^2$  <25%), moderate (I $^2$  =25-75%) or high (I $^2$  >75%).



**Figure 4** Funnel plot of analysis comparing overall recurrence at maximum follow-up (all patients).

positive cytology in the studies analysed. This may bring about the possibility that a significant proportion of stage I cancers may have been 'understaged'. Such a scenario may arise secondary to the current thoracic surgery guidelines for staging at the time of resection, which clearly request complete mediastinal lymph node resection. Positive PLC in such patients can therefore improve the accuracy of staging by identifying patients with residual microscopic disease which may not otherwise be detectable (prior to resection) and not accounted for using the TNM classification. In fact, the meta-analysis performed by Lim et al concluded that the effect of positive PLC would be to upstage a patient by one T category (up to a maximum of T4). This 'upstaging' would ultimately lead to a migration of patients from stage I to stage II, and a possible addition of postoperative chemotherapy to their treatment.

## **Strengths and limitations**

This study is the first systematic review and quantitative analysis of the evidence on the prognostic effect of pre-resection PLC on lung cancer recurrence. The validity of any meta-analytical review can potentially be compromised by heterogeneity, clinical and statistical. As we described earlier, our conclusions are statistically significant. However, we recognise the moderate to high levels of heterogeneity within our results. Variation in inclusion criteria, patient characteristics, treatment protocols and operative technique explains the clinical heterogeneity. In our case, it was the variation in patient monitoring and reporting which most likely introduced the biggest error. Most of the studies did not report the monitoring methods used for recurrence and none specified the follow-up practice. Significant intraoperative factors exist which are known to potentially influence recurrence outcome, such as differing surgical practice and variation in the incidence and management of postoperative complications. Furthermore, a difference in the cytological techniques applied for detection of cancer cells in pleural lavage fluid, and the experience of the pathologist may have had a pronounced effect.

To investigate the extent to which statistical heterogeneity might have affected our conclusions, we performed a subgroup analysis. Interestingly, for all four subgroups (yearly follow-up, study size, positive PLC <5% and quality assessment), OR and HR were >1 and statistically significant. Therefore, our conclusion that positive pre-resection PLC is a strong prognostic factor for recurrence is supported by a separate subgroup analysis.

# Lung cancer

This study can be strengthened in several ways, some of which depend on an increased level of intra-study reporting. First, although the evidence seems to demonstrate a prognostic element to positive pre-resection PLC, this finding could have been further consolidated if recurrence data had been reported separately for stage I and II disease with stages III and IV excluded. Patients diagnosed with stage III and IV disease are routinely treated for systemic disease anyway. Second, separate recurrence data for each type of non-small cell lung cancer would be welcome and would add to the conclusions. Finally, we believe that authors should report in detail all investigations used for staging. Because not all institutions have a homogenous preoperative protocol, relevant funding and/or access to advanced techniques such as PET scans, it would have been desirable to compare studies in which pre-resection PLC was combined with these techniques and those studies in which it was not. Such a comparison would allow us to perceive whether the effect of pre-resection PLC on the staging process was significant, even when applied simultaneously with advanced investigatory techniques.

# Implications of our study and conclusions

This article highlights the prognostic value of pre-resection detection of lung cancer cells in pleural wash-outs, for predicting postoperative recurrence outcomes in patients with lung cancer. It has also confirmed the findings of the two previous metanalyses by Lim *et al* and Li *et al* which highlighted a link between unfavourable survival outcomes and positive pre-resection PLC. As positive pre-resection PLC is associated with higher overall, distant and local recurrence (and lower survival rates), cytological examination of pleural lavage fluid prior to curative lung cancer surgery may prove beneficial during the initial tumour staging process and thus subsequent management decisions

Pre-resection PLC may be a standard diagnostic tool performed together with other invasive staging investigations (mediastinoscopy or mediastinotomy) before the planned operation. The techniques used will depend on the availability of trained personnel and the thoracic unit characteristics. A thoracoscopic procedure could be performed in university/teaching hospitals whereas a simple chest drain can be applied in units where minimally invasive procedures are not yet routine practice. Finally, PLC is performed prior to the resection, thus avoiding the issue of contamination encountered when performing post-resection PLC. This allows for a more definitive inference.

However, we appreciate that this meta-analysis is 'hypothesis generating' rather than conclusive and we believe that further research is required. In particular, our results suggest the need for a large-scale, multi-centre, prospective randomised trial of 'surgery' versus 'surgery and adjuvant chemotherapy' in patients with stage I disease found to have positive pre-resection PLC (with any type of recurrence as a primary endpoint). This will allow for a more scientifically rigorous approach to treatment of lung cancer.

# Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

## **REFERENCES**

- American Cancer Society. Cancer Facts and Figures 2009. American Cancer Society. http://ww2.cancer.org/downloads/STT/500809web.pdf (accessed 9 Feb 2011).
- Ries L, Eisner M, Kosary C. Cancer Statistics Review, 1975—2002. Bethesda, USA: National Cancer Institute, 2005.

- Satoh Y, Hoshi R, Ishikawa Y, et al. Recurrence patterns in patients with early stage non-small cell lung cancers undergoing positive pleural lavage cytology. Ann Thorac Surg 2007;83:197—202.
- Jiao X, Krasna MJ. Clinical significance of micrometastasis in lung and esophageal cancer: a new paradigm in thoracic oncology. Ann Thorac Surg 2002;74:278—84.
- Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997:111:1710—17.
- Li YN, Shi HZ, Liang QL, et al. Prognostic significance of pleural lavage cytology in patients with lung cancer: a meta-analysis. Lung Cancer 2008;60:183—92.
- Spjut HJ, Hendrix VJ, Ramirez GA, et al. Carcinoma cells in pleural cavity washings. Cancer 1958:11:1222—5.
- Aokage K, Yoshida J, Ishii G, et al. The impact on survival of positive intraoperative pleural lavage cytology in patients with non-small-cell lung cancer. J Thorac Cardiovasc Surg 2010;139:1246—52, 1252.e1.
- Taniguchi Y, Nakamura H, Miwa K, et al. Prognostic significance of pleural lavage cytology after thoracotomy and before closure of the chest in lung cancer. Interact Cardiovasc Thorac Surg 2009;9:102—6.
- Shintani Y, Ohta M, Iwasaki T, et al. Intraoperative pleural lavage cytology after lung resection as an independent prognostic factor for staging lung cancer. J Thorac Cardiovasc Surg 2009;137:835—9.
- Kawachi R, Nakazato Y, Masui K, et al. Clinical significance of pleural lavage cytology for non-small cell lung cancer: is surgical resection valid for patients with positive pleural lavage cytology? Interact Cardiovasc Thorac Surg 2009;9:265—8.
- Higashiyama M, Oda K, Okami J, et al. Prognostic value of intraoperative pleural lavage cytology for lung cancer without carcinomatous pleuritis: importance in patients with early stage disease during long-term follow-up. Eur J Cardiothorac Surg 2009;35:337—42
- Lim E, Clough R, Goldstraw P, et al. Impact of positive pleural lavage cytology on survival in patients having lung resection for non—small-cell lung cancer: an international individual patient data meta-analysis. J Thorac Cardiovasc Surg 2010:139:1441—6
- The Cochrane Library. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. Chichester, UK: John Wiley & Sons, Ltd, 2005.
- Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
- Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008—12.
- Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. *Trials* 2007;8:16.
- Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719

  –48.
- DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1006;7:177, 00
- Egger M, Davey Smith G, Altman DG. Systematic Reviews in Healthcare: Meta-Analysis in Context. London: BMJ Books, 1995.
- Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 1988;7:889—94.
- Stamou SC, Jablonski KA, Pfister AJ, et al. Stroke after conventional versus minimally invasive coronary artery bypass. Ann Thorac Surg 2002;74:394—9.
- England MR, Gordon G, Salem M, et al. Magnesium administration and dysrhythmias after cardiac surgery. A placebo-controlled, double-blind, randomized trial. JAMA 1992;268:2395—402.
- Higashiyama M, Doi O, Kodama K, et al. Pleural lavage cytology immediately after thoracotomy and before closure of the thoracic cavity for lung cancer without pleural effusion and dissemination: clinicopathologic and prognostic analysis. Ann Surg Oncol 1997;4:409—15.
- Buhr J, Berghäuser KH, Gonner S, et al. The prognostic significance of tumor cell detection in intraoperative pleural lavage and lung tissue cultures for patients with lung cancer. J Thorac Cardiovasc Surg 1997;113:683—90.
- Kondo H, Asamura H, Suemasu K, et al. Prognostic significance of pleural lavage cytology immediately after thoracotomy in patients with lung cancer. J Thorac Cardiovasc Surg 1993;106:1092—7.
- Nakagawa T, Okumura N, Kokado Y, et al. Clinical relevance of intraoperative pleural lavage cytology in non-small cell lung cancer. Ann Thorac Surg 2007;83:204—8.
- Vicidomini G, Santini M, Fiorello A, et al. Intraoperative pleural lavage: is it a valid prognostic factor in lung cancer? Ann Thorac Surg 2005;79:254—7.
- Tomita M, Shimizu T, Matsuzaki Y, et al. Prognostic significance of carcinoembryonic antigen level in pleural lavage fluid for patients with lung adenocarcinoma. Ann Thorac Surg 2005;80:276–81.
- Lim E, Ali A, Theodorou P, et al. Intraoperative pleural lavage cytology is an independent prognostic indicator for staging non-small cell lung cancer. J Thorac Cardiovasc Surg 2004;127:1113—18.
- Okada M, Sakamoto T, Nishio W, et al. Pleural lavage cytology in non-small cell lung cancer: lessons from 1000 consecutive resections. J Thorac Cardiovasc Surg 2003:126:1911—15
- Dresler CM, Fratelli C, Babb J. Prognostic value of positive pleural lavage in patients with lung cancer resection. Ann Thorac Surg 1999;67:1435—9.
- Hillerdal G, Dernevik L, Almgren SO, et al. Prognostic value of malignant cells in pleural lavage at thoracotomy for bronchial carcinoma. Lung Cancer 1998;21:47—52.
- Okumura M, Ohshima S, Kotake Y, et al. Intraoperative pleural lavage cytology in lung cancer patients. Ann Thorac Surg 1991;51:599—604.